BCAT2 and acute myeloid leukemia: In acute myeloid leukemia (AML), METTL16 drives tumor development by promoting the expression of branched-chain amino acid (BCAA) transaminases BCAT1 and BCAT2, reprogramming BCAA metabolism (140).